Clinical Trial Update: Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis [Phase 2]

View source ↗

Summary

Phase 2 efficacy study of a p38 kinase inhibitor in patients with atherosclerosis has completed. Sponsor: Bristol-Myers Squibb.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• p38 MAP kinase inhibitor

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Vascular Diseases | Phase 2 | Status: COMPLETED